[Ochrobactrum anthropi and polymicrobial peritonitis in peritoneal dialysis: a resistance predictor].
Quintela Obregón
E
E
Palomar Fontanet
R
R
Salas
C
C
Rodrigo Calabia
E
E
Arias Rodríguez
M
M
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D005922:Glomerulonephritis, IGA / Q000150:complications / Q000628:therapy; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D020621:Ochrobactrum anthropi / Q000187:drug effects* / Q000302:isolation & purification; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D002939:Ciprofloxacin; D015378:Imipenem; D015725:Fluconazole